Table 2.
Distributions of demographic traits in the total sample of transplant recipients and in analytic subsamples defined by the availability of source-specific immunosuppression informationa
| Parameter | Total Sample of Transplant Recipients(N = 181) | Analytic Samples Defined by the Presence of Immunosuppression Information in the Data Sources of Interest (n [%])b
|
|||
|---|---|---|---|---|---|
| OPTN, MR, or CLM(n = 178) | OPTN and MR(n = 150) | OPTN and CLM(n = 82) | MR and CLM(n = 79) | ||
| Recipient traits | |||||
| female gender | 77 (42.5) | 74 (41.6) | 62 (41.3) | 34 (41.5) | 30 (38.0) |
| race | |||||
| black | 56 (30.9) | 55 (30.9) | 44 (29.3) | 25 (30.5) | 25 (31.7) |
| white | 124 (68.5) | 122 (68.5) | 105 (70.0) | 56 (68.3) | 53 (67.1) |
| other | 1 (0.6) | 1 (0.6) | 1 (0.7) | 1 (1.2) | 1 (1.3) |
| age (yr) | |||||
| 0 to 18 | 5 (2.8) | 5 (2.8) | 4 (2.7) | 1 (1.2) | 1 (1.3) |
| 19 to 30 | 23 (12.7) | 23 (12.9) | 18 (12.0) | 13 (15.9) | 13 (16.5) |
| 31 to 44 | 47 (26.0) | 46 (25.8) | 40 (26.7) | 25 (30.5) | 22 (27.9) |
| 45 to 59 | 48 (26.5) | 47 (26.4) | 40 (26.7) | 19 (23.2) | 19 (24.1) |
| ≥60 | 58 (32.0) | 57 (32.0) | 48 (32.0) | 24 (29.3) | 24 (30.4) |
| BMI category (kg/m2) | |||||
| <10 or missing | 52 (28.7) | 52 (29.2) | 50 (33.3) | 29 (35.4) | 28 (35.4) |
| nonoverweight, nonobese (BMI <25) | 64 (35.4) | 62 (34.8) | 46 (30.7) | 28 (34.2) | 26 (32.9) |
| overweight (BMI ≥25 and <30) | 39 (21.6) | 38 (21.4) | 31 (20.7) | 16 (19.5) | 15 (19.0) |
| obese (BMI ≥30) | 26 (14.4) | 26 (14.6) | 23 (15.3) | 9 (11.0) | 10 (12.7) |
| Primary cause of ESRD | |||||
| diabetes | 37 (20.4) | 37 (20.8) | 29 (19.3) | 21 (25.6) | 21 (26.6) |
| hypertension | 14 (7.7) | 14 (7.9) | 10 (6.7) | 6 (7.3) | 6 (7.6) |
| glomerulonephritis | 13 (7.2) | 13 (7.3) | 10 (6.7) | 6 (7.3) | 6 (7.6) |
| other | 35(19.3) | 33 (18.5) | 25 (16.7) | 13 (15.9) | 10 (12.7) |
| unknown | 72 (39.8) | 71 (39.9) | 66 (44.0) | 34 (41.5) | 34 (43.0) |
| Pretransplantation comorbidities | |||||
| diabetes | 53 (29.3) | 53 (30.2) | 44 (29.3) | 27 (32.9) | 27 (34.1) |
| cerebral vascular disease | 2 (1.1) | 2 (1.2) | 1 (0.7) | 1 (1.2) | 1 (1.3) |
| malignancy | 8 (4.4) | 8 (4.6) | 8 (5.3) | 3 (3.7) | 3 (3.9) |
| peripheral vascular disease | 4 (2.2) | 4 (2.3) | 3 (2.0) | 3 (3.7) | 3 (3.9) |
| angina | 8 (4.4) | 8 (4.6) | 7 (4.7) | 4 (4.9) | 4 (5.2) |
| Deceased donor type | 143 (79.0) | 140 (78.7) | 118 (78.7) | 63 (76.8) | 60 (76.0) |
| Delayed graft function | 11 (6.1) | 10 (5.6) | 8 (5.3) | 3 (3.7) | 2 (2.5) |
| Year of transplantation | |||||
| 1998 | 45 (24.9) | 44 (24.7) | 18 (12.0) | 18 (22.0) | 17 (21.5) |
| 1999 | 38 (21.0) | 38 (21.4) | 36 (24.0) | 18 (22.0) | 17 (21.5) |
| 2000 | 46 (25.4) | 45 (25.3) | 45 (30.0) | 23 (28.1) | 23 (29.1) |
| 2001 | 52 (28.7) | 51 (28.7) | 51 (34.0) | 23 (28.1) | 22 (27.9) |
a
BMI, body mass index; CLM, Medicare pharmacy billing claims; MR, medical record; OPTN, Organ Procurement and Transplantation Network.
b
Refers to the presence of immunosuppression information at at least one study time point. Significance test were not performed as groups are not mutually exclusive.